MPLC is dominated by KRAS mutations in European and American populations (Chang et al., 2019; Mansuet-Lupo et al., 2019), likely reflecting the overall known geographic differences in genomic profiles of lung cancer. This evidence concerns the gene KRAS and lung cancer.